Oral mucositis is a clinically important and sometimes dose-limiting complication of Cancer Therapy. Mucositis lesions are painful, affect nutrition, quality of life and often hampers continuity of the treatment modality. The pathogenesis of oral mucositis is multifactorial and complex. This is a review paper which discusses various aspects a clinician should know in management of mucositis.
INTRODUCTION
Oral mucositis is a common and debilitating painful sideeffect of many forms of chemotherapy and radiation therapy. The erythematous, atrophic and ulcerative lesions that develop are a consequence of epithelial damage and death mediated through a complex series of molecular and cellular events.
The consequences of mucositis is detrimental so much that it may result in chemotherapy dose reductions, breaks in radiation, administration of narcotics, hospitalization and morbidity.
Although, the clinical impact of oral mucositis might be under-appreciated by most health care professionals, the same is certainly not held by individuals who report mucositis.
CLINICAL SIGNIFICANCE OF ORAL MUCOSITIS
The severity of oral mucositis varies from mild erythema, with mucosal discomfort and burning sensation to large, deep eroded, coalescing ulcers which render high doses of opoids for intervention. The oral cavity proves to be a good medium for the flourishing of all-bacteria, virus and fungi. Hence, mucositis is a known factor for bacteremia and sepsis.
Patients undergoing chemotherapy and radiation therapy for cancers of head and neck, show mucosal changes after a cumulative radiation dose. Ulcerative lesion begin to show-up by the end of third week, when almost 30 Gy of radiation dose is taken.
Chemotherapy-induced mucositis typically begins 4 to 5 days following the infusion and peaks 5 days later. The lesions are usually limited to nonkeratinised surfaces-like lateral and ventral surface of tongue, buccal mucosa and soft palate. Selected agents such as antimetabolites and alkylating agents cause a higher incidence and severity of oral mucositis. Effects of oral mucositis is so severe that patients opt to take breaks from their therapies leading to break in the regime planned by the oncologist. And due to inappropriate management, consequently there is suboptimal cancer treatment.
ETIOPATHOGENESIS OF ORAL MUCOSITIS
Studies show that the fundamental mechanisms involved in pathogenesis of mucositis are much more complex than direct damage to epithelium alone. 1 Mechanisms for radiation-induced and chemotherapy-induced mucositis are believed to be similar. Following is the five-staged model for the pathogenesis of mucositis. 
Ulceration and inflammation:
There is a significant inflammatory cell infiltrate associated with the mucosal ulcerations based in part on metabolic by-products of the colonizing oral microflora. Production of proinflammatory cytokines is also further up-regulated as a result of this secondary infection. 5. Healing: This phase is characterized by epithelial proliferation as well as cellular and tissue differentiation, restoring the integrity of the epithelium.
Calibration of Oral Mucositis
Many scales have been reported to describe the extent and severity of oral mucositis. *The World Health Organization (WHO) is easy and suitable for routine daily practice. It is as follows:
Grade 0
No oral mucositis
Grade 1 Erythema and soreness

Grade 2
Ulcers, able to eat solids
Grade 3
Ulcers, requires liquid diet (due to mucositis)
Grade 4
Ulcers, alimentation not possible (due to mucositis) *The national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) version 3.0 includes Abbreviation: NFκ-β = nuclear factor kappa-β; COX-2 = cyclooxygenase-2; KGF = keratinocyte growth factor; ROS = reactive oxygen species; TNF-α = tumor necrosis factor-alpha; MMPs = matrix metalioproteinases; ECM = extracellular matrix; NRF2 = nuclear factor erythroid-2 related factor 2 • Saline mouth rinses, ice chips and topical mouth rinses containing 2% viscous lignocaine is often used in most centers.
• Lidocaine + diphenhydramine + soothing or Kaopectate all in equal volumes can be mixed and administered locally. They provide shortterm relief.
• Sucrafate, a topical mucosal bioadherent which is not an anesthetic is postulated to reduce pain due to its quality of forming a protective covering over an ulcerated mucosa
Nutritional support Nutritional intake can be severely compromised by the pain associated with severe oral mucositis.
A soft diet and liquid diet supplements are more easily tolerated than a normal diet when oral mucositis is present.
In patients expected to develop severe mucositis, a gastrostomy tube is placed prophylactically, although this varies considerably from center to center.
In patients undergoing hematopoietic cell transplantation, total parenteral nutrition is usually given via an indwelling catheter such as Hickman line.
Oral decontamination It has been hypothesized that microbial colonization of oral mucositis lesions exacerbates the severity of oral mucositis and hence decontamination helps reduce mucositis.Multiple studies have demonstrated that maintenance of good oral hygiene can reduce severity of oral mucositis. [8] [9] [10] Patients who have undergone Hematopoietic cell transplantation and develop oral mucositis also have been found to be three times more likely to develop bacteremias resulting in increased length of hospital stays as compared to patients without mucositis. 11 So, oral decontamination may reduce mucositis that inturn my reduce bacteremia
Oral decontamination can reduce infection of the oral cavity by opportunistic pathogens. 12 Hence oral decontamination is to reduce the systemic sepsis from resident oral and/or opportunistic pathogens. This is especially true in patients who are immunosuppressed as a result of chemotherapy Patients and his caretakers need an emphasis on effective oral hygiene.
MASCC/ISOO guidelines recommend use of a standardized oral care protocol including brushing with a soft tooth-brush, flossing and use of nonmedicated rises; e.g. saline, sodium bicarbonate rinses.
Alcohol containing chlorhexidine mouth rinses may be difficult for patients to tolerate, hence not administered .7 Nystatin rinses is not found to be much effective .13 Systemic Fluconazole has shown significant and dramatic reduction in candidiasis and mucositis induced due to radiation therapy for HFN cancers.
MASCC/ISOO guidelines recommend against the routine use of antimicrobial lozenges of acyclovir and its analogs to prevent mucositis. Human keratinocyte 2-{Repifermin}, related compound have has shown to be ineffective in this direction 16 Intravenous human fibroblast growth factor-20
[Velafermin] is currently in clinical development for reduction of mucositis secondary to high-dose chemotherapy 17 
Antiinflammatory agents
Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that inhibits proinflammatory cytokines including TNF-α.
L-glutamine enhances the uptake of amino acid into epithelial cells. Glutamine may reduce mucosal injury by reducing the producing the production of proinflammatory cytokines and cytokine-related apoptosis and may promote healing by increasing fibroblast and collagen synthesis MASCC/ISOO guidelines recommended use of this agent in patients receiving moderate-dose radiation therapy. 18 However this agent has not received approval from FDA.
A study showed that oral suspension of Lglutamine reduced the incidence of clinically significant chemotherapy-induced oral mucositis.
MASCC/ISOO guidelines recommend that systemically administered glutamine not be used for GI mucositis because of lack of efficacy. This scale has been validated in a multicenter trial with high inter-observer reproducibility and strong correlation of objective mucositis scores with patient symptoms. 4 The eastern co-operative oncology group (ECOG) common toxicity criteria are also used in oncology trials to document severity of oral mucositis.
5
Management of Oral Mucositis
Based on a comprehensive systematic review of literature, the mucositis study group of the Multinational Association for Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) has developed clinical practice guidelines for management of mucositis 6 (Table 2 ).
SUMMARY
Oral mucositis has emerged as a clinically important complication of selected cancer therapies. The incidence of oral mucositis can be close to 100% in patients receiving certain conditioning regimens in inticipation of hematopoietic stem-cell transplant or radiation therapy, with/ without chemotherapy for cancers of head, face, neck (HFN). Two-thirds of patients being treated for cancers of the larynx or hypopharynx suffer from mucositis. It is almost ubiquitous in patients receiving induction therapy for leukemia and oral mucositis affects between 25 to 33% 22, 23 of patients who receive multicycle chemotherapy for the treatment of most common solid tumors.
Although, the condition has been evident for several decades, it is only lately new model for pathogenesis has been defined. This model has facilitated designing of effective foundation for improvising target therapies at the cellular levels. Hence newer drugs can be formulated, developed and prescribed over a period of time. This in turn would aid the health care personnel to customize therapy according to the risk for developing the condition.
